IPO - Cytonics Corp

Form Type: 253G2

Filing Date: 2025-03-17

Corporate Action: Ipo

Type: New

Accession Number: 000110465925024346

Filing Summary: Cytonics Corporation is offering up to 8,000,000 shares of Common Stock, which includes 6,666,667 shares for cash and 1,333,333 shares as Bonus Shares. Investors must purchase a minimum of 167 shares, equating to a $500 investment. Each investor will grant an irrevocable proxy to the President of the company, limiting their voting rights until specified events occur. The expected price per share is $3.00, with underwriting fees and other costs outlined, totaling approximately $4,500,000 in expenses. The offering aims to raise funds primarily for Phase 2 clinical trials for a new treatment, with the closing date for investments set at a maximum of three years from March 14, 2025. Cytonics aims to become a public reporting company under the Securities Exchange Act, highlighting its plans for future growth and compliance with regulatory requirements. The company has incurred significant historical losses and has raised questions about its ability to continue as a going concern, emphasizing the financial risks for potential investors.

Document Link: View Document